top of page
Insights for Life Sciences Talent Leaders
Strategic guidance on life sciences executive recruitment and human capital for search partners, biotech innovators, and scale-up HR leaders. I also share occasional personal reflections on the industry.


Q3 Pharma Earnings: Portfolio Renewal, Therapeutic-Area Concentration, and the Shift to Innovation-Led Growth
Q3 pharmaceutical results highlight a sector moving beyond pandemic-driven revenues toward innovation-led growth. Demand for obesity and specialty medicines is driving strong performance for companies with differentiated products, while mature and COVID-related portfolios continue to face pressure. Acquisitions and portfolio renewal are reshaping growth prospects, even as one-off costs can obscure underlying performance.
For life sciences leaders, this shift has implications
sharonshieldsconsu
Nov 95 min read


Remember, Remember the Fifth of November: Biotech’s Fireworks, Sparks and Slow Burns
Remember, remember the fifth of November—the night when bonfires burn, fireworks light the sky and everyone looks up to see what will explode next. Biotech has its own Fireworks Night. This year’s display featured headline-grabbing rockets: GLP‑1 deals, gene editing milestones, renewed enthusiasm for RNA and a more disciplined wave of AI‑in‑drug‑discovery stories. But, as every investor knows, not everything that launches reaches the same height.
For biotech insiders and inv
sharonshieldsconsu
Nov 53 min read


Radiopharmaceuticals at Scale: Can Oncology Build the Infrastructure This Modality Requires?
Radiopharmaceuticals have moved from the periphery of oncology to the centre of pipeline and dealmaking conversations. What was once a niche, technically awkward modality is now a serious strategic bet for big pharma and specialist biotechs alike.
The science is compelling: take radiation we know can kill cancer cells, and deliver it with the precision of modern targeting ligands or antibodies. Early products in prostate cancer and neuroendocrine tumours have shown that, wit
sharonshieldsconsu
Oct 214 min read


Autumn Inflection Point: Approvals, AI, & Capital Put Life Sciences in Overdrive
Autumn inflection point: approvals, AI, and capital are putting life sciences into overdrive. As summer turns to fall, the sector is accelerating, not slowing—driven by a cluster of FDA approvals in high‑unmet‑need diseases, breakthrough gene therapies, new guidance for AI‑enabled and microbiome-based technologies, and rising deal and funding activity. For biopharma leaders and investors, this late‑summer surge signals a pivotal moment to engage, partner, and deploy capital a
sharonshieldsconsu
Aug 296 min read
bottom of page